<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03617406</url>
  </required_header>
  <id_info>
    <org_study_id>3635</org_study_id>
    <nct_id>NCT03617406</nct_id>
  </id_info>
  <brief_title>Volume Challenge Added to DSE in the Diagnosis of Severe LFLGAS</brief_title>
  <acronym>FLOW-AS</acronym>
  <official_title>Volume Challenge Added to Dobutamine Stress Echocardiography in the Diagnosis of Severe Low-Flow, Low-Gradient Aortic Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test the diagnostic added value of Volume Challenge (VC) to
      low-dose dobutamine stress echocardiography (LDDSE) in patients with a low-flow, low-gradient
      aortic stenosis (LFLGAS). This study will assess if LDDSE plus VC allows to increase the
      proportion of patients in whom a true severe AS can be differentiated from a pseudo severe
      AS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The design of the study is a monocentric prospective non-randomized pilot clinical trial. A
      standard LDDSE will be performed. The stroke volume (SV) will be recorded. The addition of VC
      with the passive leg raise method at peak dobutamine dose will be performed. A
      transesophageal echocardiography (TEE) with low dose dobutamine and a bolus of normal saline
      will be performed as a validation method to measure AVA with the planimetry method. The SV
      will be recorded. Proportion of patient receiving the diagnosis of true severe AS defined as
      a combination of AVA &lt;1.0 cm2 and ∆SV ≥ 20% will be compared between standard LDDSE and LDDSE
      with addition of VC. Calculating sensitivity, specificity, performing ROC curve analysis and
      calculating the Youden-index, the accuracy of the test method (LDDSE plus passive leg
      raising) for the detection of truly severe AS in comparison with the reference method (TEE)
      will be determined.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnosis of true severe AS</measure>
    <time_frame>Measures taken during echocardiograph a few minutes after administration of VC</time_frame>
    <description>Proportion of patients receiving the diagnosis of true severe AS defined as a combination of AVA &lt;1.0 cm2 and ∆SV ≥ 20% will be compared between standard LDDSE and LDDSE with addition of VC</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Arm Volume Challenge</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A standard LDDSE will be performed. The stroke volume (SV) will be recorded. The addition of VC with the passive leg raise method at peak dobutamine dose will be performed. A TEE with low dose dobutamine and a bolus of normal saline will be performed as a validation method.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Volume Challenge</intervention_name>
    <description>Addition volume challenge with passive leg raising method in LDDSE as well as administration of normal saline and dobutamine during TEE</description>
    <arm_group_label>Arm Volume Challenge</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Written informed consent

          -  Patients with LFLGAS (mean Gradient: &lt; 40 mmHg, AVA ≤ 1.0 cm2 (by continuity equation
             using LVOT diameter) SVI ≤ 35 ml/m2), by rest TTE

        Exclusion Criteria:

          -  Hypersensitivity to dobutamine or midazolam

          -  Lack of safe contraception defined as: Female participants of childbearing potential
             not using and not willing to continue contraception for study duration, such as oral,
             injectable, or implantable contraceptives, or intrauterine contraceptive devices.

          -  Inability to follow the procedures of the study, e.g. due to language problems,
             psychological disorders, dementia, etc.,

          -  Enrolment of the investigator, his/her family members, employees and other dependent
             persons

          -  Previous enrolment into the current study,

        ADDITIONAL SPECIFIC EXCLUSION CRITERIA REGARDING STRESS ECHOCARDIOGRAPHY:

          -  Systolic left ventricular ejection fraction (LVEF) &lt; 20%

          -  More than mild aortic regurgitation

          -  Mitral valve disease, defined by mitral valve area &lt; 2.0 cm2 or more than mild mitral
             regurgitation

          -  Unstable angina

          -  Acute pulmonary oedema

          -  Signs of relevant left ventricular heart failure defined as crackles more than one
             fourth of lung field on auscultation

          -  Signs of relevant right ventricular heart failure defined as central venous pressure
             (CVP) &gt; 15 mmHg estimated with dilatation and collapsibility of vena cava inferior
             (VCI)

          -  Severe pulmonary, renal or hepatic disease

        ADDITIONAL SPECIFIC EXCLUSION CRITERIA REGARDING TRANSESOPHAGEAL ECHOCARDIOGRAPHY:

          -  Oesophageal varices

          -  History of bariatric surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Seiler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinic for Cardiology, Inselspital, Bern</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefano de Marchi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Clinic for Cardiology, Inselspital, Bern</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Seiler, MD</last_name>
    <phone>+41 31 632 36 93</phone>
    <email>christian.seiler@insel.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eric Buffle, MD</last_name>
    <phone>+41 31 632 38 21</phone>
    <email>eric.buffle@insel.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bern University hospital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Seiler, MD</last_name>
      <phone>+41 31 632 36 93</phone>
      <email>christian.seiler@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Stefano de Marchi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Buffle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 31, 2018</study_first_submitted>
  <study_first_submitted_qc>July 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2018</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low - flow</keyword>
  <keyword>Low - gradient</keyword>
  <keyword>Low - dose dobutamine</keyword>
  <keyword>Volume challenge</keyword>
  <keyword>Echocardiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

